0001209191-20-054622.txt : 20201013 0001209191-20-054622.hdr.sgml : 20201013 20201013160447 ACCESSION NUMBER: 0001209191-20-054622 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201012 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRICE MICHAEL DENNIS CENTRAL INDEX KEY: 0001247313 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38137 FILM NUMBER: 201236305 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001662524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472608175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-207-0202 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-12 1 0001662524 AKCEA THERAPEUTICS, INC. AKCA 0001247313 PRICE MICHAEL DENNIS C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210 0 1 0 0 Chief Financial Officer Common Stock 2020-10-12 4 U 0 50000 18.15 D 0 D Stock Option (right to buy) 14.78 2020-10-12 4 D 0 300000 3.37 D 2030-05-17 Common Stock 300000 0 D This option, which provided that 1/4th of the shares would vest one year after May 18, 2020 and that 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,011,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. /s/ Joshua F. Patterson, Attorney-in-Fact 2020-10-12